Skip to main content
Journal ArticleOPEN ACCESS

Raxibacumab for the Treatment of Inhalational Anthrax

  • Migone T
  • Subramanian G
  • Zhong J
  • et al.
New England Journal of Medicine (2009) 361(2) 135-144
DOI: 10.1056/nejmoa0810603
251Citations
Citations of this article
182Readers
Mendeley users who have this article in their library.

Abstract

Inhalational anthrax caused by Bacillus anthracis is associated with high mortality primarily due to toxin-mediated injury. Raxibacumab is a human IgG1lambda monoclonal antibody directed against protective antigen, a component of the anthrax toxin.

Cite

CITATION STYLE

APA

Migone, T.-S., Subramanian, G. M., Zhong, J., Healey, L. M., Corey, A., Devalaraja, M., … Bolmer, S. D. (2009). Raxibacumab for the Treatment of Inhalational Anthrax. New England Journal of Medicine, 361(2), 135–144. https://doi.org/10.1056/nejmoa0810603

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free